CAR T-cell immunotherapy: a powerful weapon for fighting hematological B-cell malignancies

The current standard of care in hematological malignancies has brought considerable clinical benefits to patients. However, important bottlenecks still limit optimal achievements following a current medical practice. The genetic complexity of the diseases and the heterogeneity of tumor clones cause...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers of medicine 2021-12, Vol.15 (6), p.783-804
Main Authors: Mi, Jianqing, Xu, Jie, Zhou, Jianfeng, Zhao, Weili, Chen, Zhu, Melenhorst, J. Joseph, Chen, Saijuan
Format: Article
Language:English
Subjects:
CAR T cells
Hematologic Neoplasms - therapy
hematological malignancies
Hematology
Humans
Immunotherapy
Immunotherapy - adverse effects
Medicine
Medicine & Public Health
Neoplasms
Receptors, Chimeric Antigen
Review
T-Lymphocytes
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The current standard of care in hematological malignancies has brought considerable clinical benefits to patients. However, important bottlenecks still limit optimal achievements following a current medical practice. The genetic complexity of the diseases and the heterogeneity of tumor clones cause difficulty in ensuring long-term efficacy of conventional treatments for most hematological disorders. Consequently, new treatment strategies are necessary to improve clinical outcomes. Chimeric antigen receptor T-cell (CAR T) immunotherapy opens a new path for targeted therapy of hematological malignancies. In this review, through a representative case study, we summarize the current experience of CAR T-cell therapy, the management of common side effects, the causative mechanisms of therapy resistance, and new strategies to improve the efficacy of CAR T-cell therapy.
ISSN:2095-0217
2095-0225
DOI:10.1007/s11684-021-0904-z